Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 178

1.

Characteristics of mismatch repair deficiency in sarcomas.

Doyle LA, Nowak JA, Nathenson MJ, Thornton K, Wagner AJ, Johnson JM, Albrayak A, George S, Sholl LM.

Mod Pathol. 2019 Feb 14. doi: 10.1038/s41379-019-0202-3. [Epub ahead of print]

PMID:
30765880
2.

Characteristics and Outcomes of Patients With Metastatic KRAS-Mutant Lung Adenocarcinomas: The Lung Cancer Mutation Consortium Experience.

El Osta B, Behera M, Kim S, Berry LD, Sica G, Pillai RN, Owonikoko TK, Kris MG, Johnson BE, Kwiatkowski DJ, Sholl LM, Aisner DL, Bunn PA, Khuri FR, Ramalingam SS.

J Thorac Oncol. 2019 Feb 5. pii: S1556-0864(19)30097-8. doi: 10.1016/j.jtho.2019.01.020. [Epub ahead of print]

PMID:
30735816
3.

Incidental non-neoplastic parenchymal findings in patients undergoing lung resection for mass lesions.

Hung YP, Hunninghake GM, Miller ER, Putman R, Nishino M, Araki T, Hatabu H, Sholl LM, Vivero M.

Hum Pathol. 2019 Jan 15. pii: S0046-8177(19)30006-1. doi: 10.1016/j.humpath.2019.01.002. [Epub ahead of print]

PMID:
30658062
4.

Identification of diverse activating mutations of the RAS-MAPK pathway in histiocytic sarcoma.

Shanmugam V, Griffin GK, Jacobsen ED, Fletcher CDM, Sholl LM, Hornick JL.

Mod Pathol. 2019 Jan 9. doi: 10.1038/s41379-018-0200-x. [Epub ahead of print]

PMID:
30626916
5.

Best Practices Recommendations for Diagnostic Immunohistochemistry in Lung Cancer.

Yatabe Y, Dacic S, Borczuk AC, Warth A, Russell PA, Lantuejoul S, Beasley MB, Thunnissen E, Pelosi G, Rekhtman N, Bubendorf L, Mino-Kenudson M, Yoshida A, Geisinger KR, Noguchi M, Chirieac LR, Bolting J, Chung JH, Chou TY, Chen G, Poleri C, Lopez-Rios F, Papotti M, Sholl LM, Roden AC, Travis WD, Hirsch FR, Kerr KM, Tsao MS, Nicholson AG, Wistuba I, Moreira AL.

J Thorac Oncol. 2019 Mar;14(3):377-407. doi: 10.1016/j.jtho.2018.12.005. Epub 2018 Dec 18.

PMID:
30572031
6.

Lung Adenocarcinoma Syndecan-2 Potentiates Cell Invasiveness.

Tsoyi K, Osorio JC, Chu SG, Fernandez IE, Poli S, Sholl L, Cui Y, Tellez CS, Siegfried JM, Belinsky SA, Perrella MA, El-Chemaly S, Rosas IO.

Am J Respir Cell Mol Biol. 2018 Dec 18. doi: 10.1165/rcmb.2018-0118OC. [Epub ahead of print]

PMID:
30562054
7.

Suppression of STING Associated with LKB1 Loss in KRAS-Driven Lung Cancer.

Kitajima S, Ivanova E, Guo S, Yoshida R, Campisi M, Sundararaman SK, Tange S, Mitsuishi Y, Thai TC, Masuda S, Piel BP, Sholl LM, Kirschmeier PT, Paweletz CP, Watanabe H, Yajima M, Barbie DA.

Cancer Discov. 2019 Jan;9(1):34-45. doi: 10.1158/2159-8290.CD-18-0689. Epub 2018 Oct 8.

PMID:
30297358
8.

Success of genomic profiling of non-small cell lung cancer biopsies obtained by trans-thoracic percutaneous needle biopsy.

Gill RR, Murphy DJ, Kravets S, Sholl LM, Janne PA, Johnson BE.

J Surg Oncol. 2018 Dec;118(7):1170-1177. doi: 10.1002/jso.25241. Epub 2018 Sep 27.

PMID:
30261097
9.

Recognizing the Challenges of Oncogene Fusion Detection: A Critical Step toward Optimal Selection of Lung Cancer Patients for Targeted Therapies.

Sholl LM.

J Thorac Oncol. 2018 Oct;13(10):1433-1435. doi: 10.1016/j.jtho.2018.08.002. No abstract available.

PMID:
30244848
10.

Reply to Petals and thorns in programmed death-ligand 1 testing: Is all non-small cell lung cancer diagnostic material suitable?

Russell-Goldman E, Sholl LM, Vivero M.

Cancer Cytopathol. 2018 Sep;126(9):819-820. doi: 10.1002/cncy.22032. Epub 2018 Sep 21. No abstract available.

PMID:
30239144
11.

Diagnostic and Predictive Immunohistochemistry for Non-Small Cell Lung Carcinomas.

Hung YP, Sholl LM.

Adv Anat Pathol. 2018 Nov;25(6):374-386. doi: 10.1097/PAP.0000000000000206. Review.

PMID:
30188361
12.

PD-L1 expression, tumor mutational burden, and response to immunotherapy in patients with MET exon 14 altered lung cancers.

Sabari JK, Leonardi GC, Shu CA, Umeton R, Montecalvo J, Ni A, Chen R, Dienstag J, Mrad C, Bergagnini I, Lai WV, Offin M, Arbour KC, Plodkowski AJ, Halpenny DF, Paik PK, Li BT, Riely GJ, Kris MG, Rudin CM, Sholl LM, Nishino M, Hellmann MD, Rekhtman N, Awad MM, Drilon A.

Ann Oncol. 2018 Oct 1;29(10):2085-2091. doi: 10.1093/annonc/mdy334.

PMID:
30165371
13.

Genomic correlates of response to immune checkpoint blockade in microsatellite-stable solid tumors.

Miao D, Margolis CA, Vokes NI, Liu D, Taylor-Weiner A, Wankowicz SM, Adeegbe D, Keliher D, Schilling B, Tracy A, Manos M, Chau NG, Hanna GJ, Polak P, Rodig SJ, Signoretti S, Sholl LM, Engelman JA, Getz G, Jänne PA, Haddad RI, Choueiri TK, Barbie DA, Haq R, Awad MM, Schadendorf D, Hodi FS, Bellmunt J, Wong KK, Hammerman P, Van Allen EM.

Nat Genet. 2018 Sep;50(9):1271-1281. doi: 10.1038/s41588-018-0200-2. Epub 2018 Aug 27.

14.

Targeted Genomic Profiling of Female Adnexal Tumors of Probable Wolffian Origin (FATWO).

Mirkovic J, Dong F, Sholl LM, Garcia E, Lindeman N, MacConaill L, Crum CP, Nucci MR, McCluggage WG, Howitt BE.

Int J Gynecol Pathol. 2018 Aug 21. doi: 10.1097/PGP.0000000000000545. [Epub ahead of print]

PMID:
30134342
15.

Assessment of Resistance Mechanisms and Clinical Implications in Patients With EGFR T790M-Positive Lung Cancer and Acquired Resistance to Osimertinib.

Oxnard GR, Hu Y, Mileham KF, Husain H, Costa DB, Tracy P, Feeney N, Sholl LM, Dahlberg SE, Redig AJ, Kwiatkowski DJ, Rabin MS, Paweletz CP, Thress KS, Jänne PA.

JAMA Oncol. 2018 Nov 1;4(11):1527-1534. doi: 10.1001/jamaoncol.2018.2969.

PMID:
30073261
16.

Amplification of Wild-type KRAS Imparts Resistance to Crizotinib in MET Exon 14 Mutant Non-Small Cell Lung Cancer.

Bahcall M, Awad MM, Sholl LM, Wilson FH, Xu M, Wang S, Palakurthi S, Choi J, Ivanova EV, Leonardi GC, Ulrich BC, Paweletz CP, Kirschmeier PT, Watanabe M, Baba H, Nishino M, Nagy RJ, Lanman RB, Capelletti M, Chambers ES, Redig AJ, VanderLaan PA, Costa DB, Imamura Y, Jänne PA.

Clin Cancer Res. 2018 Dec 1;24(23):5963-5976. doi: 10.1158/1078-0432.CCR-18-0876. Epub 2018 Aug 2.

PMID:
30072474
17.

Understanding patterns of pathologic response following neoadjuvant immunotherapy for solid tumors.

Sholl LM.

Ann Oncol. 2018 Aug 1;29(8):1630-1632. doi: 10.1093/annonc/mdy227. No abstract available.

PMID:
30052725
18.

Tumor innate immunity primed by specific interferon-stimulated endogenous retroviruses.

Cañadas I, Thummalapalli R, Kim JW, Kitajima S, Jenkins RW, Christensen CL, Campisi M, Kuang Y, Zhang Y, Gjini E, Zhang G, Tian T, Sen DR, Miao D, Imamura Y, Thai T, Piel B, Terai H, Aref AR, Hagan T, Koyama S, Watanabe M, Baba H, Adeni AE, Lydon CA, Tamayo P, Wei Z, Herlyn M, Barbie TU, Uppaluri R, Sholl LM, Sicinska E, Sands J, Rodig S, Wong KK, Paweletz CP, Watanabe H, Barbie DA.

Nat Med. 2018 Aug;24(8):1143-1150. doi: 10.1038/s41591-018-0116-5. Epub 2018 Jul 23.

19.

Liquid biopsy of fine-needle aspiration supernatant for lung cancer genotyping.

Guibert N, Tsukada H, Hwang DH, Chambers E, Cibas ES, Bale T, Supplee J, Ulrich B, Sholl LM, Paweletz CP, Oxnard GR.

Lung Cancer. 2018 Aug;122:72-75. doi: 10.1016/j.lungcan.2018.05.024. Epub 2018 May 25.

PMID:
30032849
20.

Validation of a targeted next-generation sequencing approach to detect mismatch repair deficiency in colorectal adenocarcinoma.

Papke DJ Jr, Nowak JA, Yurgelun MB, Frieden A, Srivastava A, Lindeman NI, Sholl LM, MacConaill LE, Dong F.

Mod Pathol. 2018 Dec;31(12):1882-1890. doi: 10.1038/s41379-018-0091-x. Epub 2018 Jun 28.

PMID:
29955144
21.

Liquid Biopsy for Advanced Non-Small Cell Lung Cancer (NSCLC): A Statement Paper from the IASLC.

Rolfo C, Mack PC, Scagliotti GV, Baas P, Barlesi F, Bivona TG, Herbst RS, Mok TS, Peled N, Pirker R, Raez LE, Reck M, Riess JW, Sequist LV, Shepherd FA, Sholl LM, Tan DSW, Wakelee HA, Wistuba II, Wynes MW, Carbone DP, Hirsch FR, Gandara DR.

J Thorac Oncol. 2018 Sep;13(9):1248-1268. doi: 10.1016/j.jtho.2018.05.030. Epub 2018 Jun 6. Review.

PMID:
29885479
22.

Immunohistochemical and molecular analysis of spitzoid neoplasms with pulverocyte subclones.

Amin SM, Haugh AM, Bubley JA, Verzì AE, Merkel EA, Lee CY, Quan VL, Garfield EM, Sholl LM, Zhang B, Gerami P.

Clin Exp Dermatol. 2018 Oct;43(7):782-789. doi: 10.1111/ced.13556. Epub 2018 May 20.

PMID:
29779219
23.

STK11/LKB1 Mutations and PD-1 Inhibitor Resistance in KRAS-Mutant Lung Adenocarcinoma.

Skoulidis F, Goldberg ME, Greenawalt DM, Hellmann MD, Awad MM, Gainor JF, Schrock AB, Hartmaier RJ, Trabucco SE, Gay L, Ali SM, Elvin JA, Singal G, Ross JS, Fabrizio D, Szabo PM, Chang H, Sasson A, Srinivasan S, Kirov S, Szustakowski J, Vitazka P, Edwards R, Bufill JA, Sharma N, Ou SI, Peled N, Spigel DR, Rizvi H, Aguilar EJ, Carter BW, Erasmus J, Halpenny DF, Plodkowski AJ, Long NM, Nishino M, Denning WL, Galan-Cobo A, Hamdi H, Hirz T, Tong P, Wang J, Rodriguez-Canales J, Villalobos PA, Parra ER, Kalhor N, Sholl LM, Sauter JL, Jungbluth AA, Mino-Kenudson M, Azimi R, Elamin YY, Zhang J, Leonardi GC, Jiang F, Wong KK, Lee JJ, Papadimitrakopoulou VA, Wistuba II, Miller VA, Frampton GM, Wolchok JD, Shaw AT, Jänne PA, Stephens PJ, Rudin CM, Geese WJ, Albacker LA, Heymach JV.

Cancer Discov. 2018 Jul;8(7):822-835. doi: 10.1158/2159-8290.CD-18-0099. Epub 2018 May 17.

PMID:
29773717
24.

A Disintegrin and Metalloproteinase Domain-8: A Novel Protective Proteinase in Chronic Obstructive Pulmonary Disease.

Polverino F, Rojas-Quintero J, Wang X, Petersen H, Zhang L, Gai X, Higham A, Zhang D, Gupta K, Rout A, Yambayev I, Pinto-Plata V, Sholl LM, Cunoosamy D, Celli BR, Goldring J, Singh D, Tesfaigzi Y, Wedzicha J, Olsson H, Owen CA.

Am J Respir Crit Care Med. 2018 Nov 15;198(10):1254-1267. doi: 10.1164/rccm.201707-1331OC.

25.

Interpathologist Diagnostic Agreement for Non-Small Cell Lung Carcinomas Using Current and Recent Classifications.

Funkhouser WK Jr, Hayes DN, Moore DT, Funkhouser WK 3rd, Fine JP, Jo H, Nikolaishvilli-Feinberg N, Eeva M, Grilley-Olson JE, Banks PM, Graziano P, Boswell EL, Elmberger G, Raparia K, Hart CF, Sholl LM, Nolan NJ, Fritchie KJ, Pouagare E, Allen TC, Volmar KE, Biddinger PW, Kleven DT, Papez MJ, Spencer DV, Rekhtman N, Mino-Kenudson M, Hariri L, Driver B, Cagle PT.

Arch Pathol Lab Med. 2018 Dec;142(12):1537-1548. doi: 10.5858/arpa.2017-0481-OA. Epub 2018 Apr 30.

PMID:
29708428
26.

Immunohistochemical Detection and Molecular Characterization of IDH-mutant Sinonasal Undifferentiated Carcinomas.

Mito JK, Bishop JA, Sadow PM, Stelow EB, Faquin WC, Mills SE, Krane JF, French CA, Fletcher CDM, Hornick JL, Sholl LM, Jo VY.

Am J Surg Pathol. 2018 Aug;42(8):1067-1075. doi: 10.1097/PAS.0000000000001064.

PMID:
29683816
27.

Meningioma transcription factors link cell lineage with systemic metabolic cues.

Du Z, Brewster R, Merrill PH, Chmielecki J, Francis J, Aizer A, Abedalthagafi M, Sholl LM, Geffers L, Alexander B, Santagata S.

Neuro Oncol. 2018 Sep 3;20(10):1331-1343. doi: 10.1093/neuonc/noy057.

PMID:
29660031
28.

An Acquired NRAS Q61K Mutation in BRAF V600E-Mutant Lung Adenocarcinoma Resistant to Dabrafenib Plus Trametinib.

Abravanel DL, Nishino M, Sholl LM, Ambrogio C, Awad MM.

J Thorac Oncol. 2018 Aug;13(8):e131-e133. doi: 10.1016/j.jtho.2018.03.026. Epub 2018 Apr 6. No abstract available.

PMID:
29631033
29.

Sarcoid-Like Granulomatosis of the Lung Related to Immune-Checkpoint Inhibitors: Distinct Clinical and Imaging Features of a Unique Immune-Related Adverse Event.

Nishino M, Sholl LM, Awad MM, Hatabu H, Armand P, Hodi FS.

Cancer Immunol Res. 2018 Jun;6(6):630-635. doi: 10.1158/2326-6066.CIR-17-0715. Epub 2018 Apr 5.

PMID:
29622582
30.

Phase I Trial of a Tablet Formulation of Pilaralisib, a Pan-Class I PI3K Inhibitor, in Patients with Advanced Solid Tumors.

Edelman G, Rodon J, Lager J, Castell C, Jiang J, Van Allen EM, Wagle N, Lindeman NI, Sholl LM, Shapiro GI.

Oncologist. 2018 Apr;23(4):401-e38. doi: 10.1634/theoncologist.2017-0691. Epub 2018 Mar 28.

31.

Cabozantinib in Patients with Advanced Merkel Cell Carcinoma.

Rabinowits G, Lezcano C, Catalano PJ, McHugh P, Becker H, Reilly MM, Huang J, Tyagi A, Thakuria M, Bresler SC, Sholl LM, Shapiro GI, Haddad R, DeCaprio JA.

Oncologist. 2018 Jul;23(7):814-821. doi: 10.1634/theoncologist.2017-0552. Epub 2018 Feb 14.

PMID:
29445030
32.

Cytologic-histologic correlation of programmed death-ligand 1 immunohistochemistry in lung carcinomas.

Russell-Goldman E, Kravets S, Dahlberg SE, Sholl LM, Vivero M.

Cancer Cytopathol. 2018 Apr;126(4):253-263. doi: 10.1002/cncy.21973. Epub 2018 Feb 5.

PMID:
29405663
33.

Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors: Guideline From the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology.

Lindeman NI, Cagle PT, Aisner DL, Arcila ME, Beasley MB, Bernicker EH, Colasacco C, Dacic S, Hirsch FR, Kerr K, Kwiatkowski DJ, Ladanyi M, Nowak JA, Sholl L, Temple-Smolkin R, Solomon B, Souter LH, Thunnissen E, Tsao MS, Ventura CB, Wynes MW, Yatabe Y.

J Mol Diagn. 2018 Mar;20(2):129-159. doi: 10.1016/j.jmoldx.2017.11.004. Epub 2018 Jan 23.

PMID:
29398453
34.

Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors: Guideline From the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology.

Lindeman NI, Cagle PT, Aisner DL, Arcila ME, Beasley MB, Bernicker EH, Colasacco C, Dacic S, Hirsch FR, Kerr K, Kwiatkowski DJ, Ladanyi M, Nowak JA, Sholl L, Temple-Smolkin R, Solomon B, Souter LH, Thunnissen E, Tsao MS, Ventura CB, Wynes MW, Yatabe Y.

J Thorac Oncol. 2018 Mar;13(3):323-358. doi: 10.1016/j.jtho.2017.12.001. Epub 2018 Jan 25.

35.

Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors: Guideline From the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology.

Lindeman NI, Cagle PT, Aisner DL, Arcila ME, Beasley MB, Bernicker EH, Colasacco C, Dacic S, Hirsch FR, Kerr K, Kwiatkowski DJ, Ladanyi M, Nowak JA, Sholl L, Temple-Smolkin R, Solomon B, Souter LH, Thunnissen E, Tsao MS, Ventura CB, Wynes MW, Yatabe Y.

Arch Pathol Lab Med. 2018 Mar;142(3):321-346. doi: 10.5858/arpa.2017-0388-CP. Epub 2018 Jan 22. Review.

PMID:
29355391
36.

Interactive or static reports to guide clinical interpretation of cancer genomics.

Gray SW, Gagan J, Cerami E, Cronin AM, Uno H, Oliver N, Lowenstein C, Lederman R, Revette A, Suarez A, Lee C, Bryan J, Sholl L, Van Allen EM.

J Am Med Inform Assoc. 2018 May 1;25(5):458-464. doi: 10.1093/jamia/ocx150.

37.

Radiological features and metastatic patterns of thymic neuroendocrine tumours.

Araki T, Sholl LM, Hatabu H, Nishino M.

Clin Radiol. 2018 May;73(5):479-484. doi: 10.1016/j.crad.2017.11.025. Epub 2018 Jan 6.

PMID:
29310810
38.

The Impact of Smoking and TP53 Mutations in Lung Adenocarcinoma Patients with Targetable Mutations-The Lung Cancer Mutation Consortium (LCMC2).

Aisner DL, Sholl LM, Berry LD, Rossi MR, Chen H, Fujimoto J, Moreira AL, Ramalingam SS, Villaruz LC, Otterson GA, Haura E, Politi K, Glisson B, Cetnar J, Garon EB, Schiller J, Waqar SN, Sequist LV, Brahmer J, Shyr Y, Kugler K, Wistuba II, Johnson BE, Minna JD, Kris MG, Bunn PA, Kwiatkowski DJ; LCMC2 investigators.

Clin Cancer Res. 2018 Mar 1;24(5):1038-1047. doi: 10.1158/1078-0432.CCR-17-2289. Epub 2017 Dec 7.

39.

Implications of the tumor immune microenvironment for staging and therapeutics.

Taube JM, Galon J, Sholl LM, Rodig SJ, Cottrell TR, Giraldo NA, Baras AS, Patel SS, Anders RA, Rimm DL, Cimino-Mathews A.

Mod Pathol. 2018 Feb;31(2):214-234. doi: 10.1038/modpathol.2017.156. Epub 2017 Dec 1. Review.

40.

Epitope mapping of spontaneous autoantibodies to anaplastic lymphoma kinase (ALK) in non-small cell lung cancer.

Awad MM, Mastini C, Blasco RB, Mologni L, Voena C, Mussolin L, Mach SL, Adeni AE, Lydon CA, Sholl LM, Jänne PA, Chiarle R.

Oncotarget. 2017 Sep 23;8(54):92265-92274. doi: 10.18632/oncotarget.21182. eCollection 2017 Nov 3.

41.

Molecular diagnostics of lung cancer in the clinic.

Sholl L.

Transl Lung Cancer Res. 2017 Oct;6(5):560-569. doi: 10.21037/tlcr.2017.08.03. Review.

42.

Targeted Genomic Profiling Reveals Recurrent KRAS Mutations in Mesonephric-like Adenocarcinomas of the Female Genital Tract.

Mirkovic J, McFarland M, Garcia E, Sholl LM, Lindeman N, MacConaill L, Dong F, Hirsch M, Nucci MR, Quick CM, Crum CP, McCluggage WG, Howitt BE.

Am J Surg Pathol. 2018 Feb;42(2):227-233. doi: 10.1097/PAS.0000000000000958.

PMID:
28984674
43.

Next-Generation Sequencing from Liquid Biopsies in Lung Cancer Patients: Advances in Comprehensive Biomarker Testing.

Sholl LM.

J Thorac Oncol. 2017 Oct;12(10):1464-1466. doi: 10.1016/j.jtho.2017.08.004. No abstract available.

44.

Histopathology of Interstitial Lung Abnormalities in the Context of Lung Nodule Resections.

Miller ER, Putman RK, Vivero M, Hung Y, Araki T, Nishino M, Washko GR, Rosas IO, Hatabu H, Sholl LM, Hunninghake GM.

Am J Respir Crit Care Med. 2018 Apr 1;197(7):955-958. doi: 10.1164/rccm.201708-1679LE. No abstract available.

PMID:
28934558
45.

Diffuse Staining for Activated NOTCH1 Correlates With NOTCH1 Mutation Status and Is Associated With Worse Outcome in Adenoid Cystic Carcinoma.

Sajed DP, Faquin WC, Carey C, Severson EA, H Afrogheh A, A Johnson C, Blacklow SC, Chau NG, Lin DT, Krane JF, Jo VY, Garcia JJ, Sholl LM, Aster JC.

Am J Surg Pathol. 2017 Nov;41(11):1473-1482. doi: 10.1097/PAS.0000000000000945.

46.

Thoracic Complications of Precision Cancer Therapies: A Practical Guide for Radiologists in the New Era of Cancer Care.

Nishino M, Hatabu H, Sholl LM, Ramaiya NH.

Radiographics. 2017 Sep-Oct;37(5):1371-1387. doi: 10.1148/rg.2017170015. Review.

47.

GNAS mutations in primary mucinous and non-mucinous lung adenocarcinomas.

Ritterhouse LL, Vivero M, Mino-Kenudson M, Sholl LM, Iafrate AJ, Nardi V, Dong F.

Mod Pathol. 2017 Dec;30(12):1720-1727. doi: 10.1038/modpathol.2017.88. Epub 2017 Aug 4.

48.

The fuzzy world of precision medicine: deliberations of a precision medicine tumor board.

McGraw SA, Garber J, Jänne PA, Lindeman N, Oliver N, Sholl LM, Van Allen EM, Wagle N, Garraway LA, Joffe S, Gray SW.

Per Med. 2017 Jan;14(1):37-50. doi: 10.2217/pme-2016-0074. Epub 2016 Dec 15.

49.

Next-generation sequencing of cytologic preparations: An analysis of quality metrics.

Hwang DH, Garcia EP, Ducar MD, Cibas ES, Sholl LM.

Cancer Cytopathol. 2017 Oct;125(10):786-794. doi: 10.1002/cncy.21897. Epub 2017 Jul 20.

50.

Immunohistochemistry of Pulmonary Biomarkers: A Perspective From Members of the Pulmonary Pathology Society.

Thunnissen E, Allen TC, Adam J, Aisner DL, Beasley MB, Borczuk AC, Cagle PT, Capelozzi VL, Cooper W, Hariri LP, Kern I, Lantuejoul S, Miller R, Mino-Kenudson M, Radonic T, Raparia K, Rekhtman N, Roy-Chowdhuri S, Russell P, Schneider F, Sholl LM, Tsao MS, Vivero M, Yatabe Y.

Arch Pathol Lab Med. 2018 Mar;142(3):408-419. doi: 10.5858/arpa.2017-0106-SA. Epub 2017 Jul 7.

PMID:
28686497

Supplemental Content

Support Center